Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada
Chua, A.; Perrin, A.; Ricci, J.F.; Neary, M.P.; Thabane, M.
Current Oncology 25(4): E354-E355
2018
ISSN/ISBN: 1718-7729
PMID: 30111982
DOI: 10.3747/co.25.4233
Accession: 062402876
[This corrects the article on p. 32 in vol. 25, PMID: 29507481.].
PDF emailed within 0-6 h: $19.90
Related References
Chua, A.; Perrin, A.; Ricci, J.F.; Neary, M.P.; Thabane, M. 2018: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada Current Oncology 25(1): 32-40Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.B.; Rouyrre, N.; Sachs, C.; Valle, J.W.; Fave, G.D.; Van Cutsem, E.; Tesselaar, M.; Shimada, Y.; Oh, D.-Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E. 2016: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 387(10022): 968-977
Rose, D.B.; Nellesen, D.; Neary, M.P.; Cai, B. 2017: Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic Journal of Medical Economics 20(4): 395-404
Mujica-Mota, R.; Varley-Campbell, J.; Tikhonova, I.; Cooper, C.; Griffin, E.; Haasova, M.; Peters, J.; Lucherini, S.; Talens-Bou, J.; Long, L.; Sherriff, D.; Napier, M.; Ramage, J.; Hoyle, M. 2018: Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis Health Technology Assessment 22(49): 1-326
Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G. 2015: 5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study European Journal of Cancer 51: S709-S710
Yao, J.C.; Oh, D.-Y.; Qian, J.; Park, Y.S.; Herbst, F.; Ridolfi, A.; Izquierdo, M.; Ito, T.; Jia, L.; Komoto, I.; Sriuranpong, V.; Shimada, Y. 2019: Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study Oncotargets and Therapy 12: 1717-1728
Pavel, M.E.; Singh, S.; Strosberg, J.R.; Bubuteishvili-Pacaud, L.; Degtyarev, E.; Neary, M.P.; Carnaghi, C.; Tomasek, J.; Wolin, E.; Raderer, M.; Lahner, H.; Valle, J.W.; Pommier, R.; Van Cutsem, E.; Tesselaar, M.E.T.; Fave, G.D.; Buzzoni, R.; Hunger, M.; Eriksson, J.; Cella, D.; Ricci, J.-F.ço.; Fazio, N.; Kulke, M.H.; Yao, J.C. 2017: Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial LANCET. Oncology 18(10): 1411-1422
Huse, D.M.; von Mehren, M.; Lenhart, G.; Joensuu, H.; Blanke, C.; Feng, W.; Finkelstein, S.; Demetri, G. 2007: Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours Clinical Drug Investigation 27(2): 85-93
Nakayama, Y.; Ikeda, M.; Kojima, M.; Goto, K.; Hara, M.; Okuyama, H.; Takahashi, H.; Ohno, I.; Shimizu, S.; Mitsunaga, S.; Okusaka, T. 2013: Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report ChemoTherapy 59(1): 74-78
Yao, J.C.; Singh, S.; Wolin, E.; Voi, M.; Pacaud, L.B.; Lincy, J.; Sachs, C.; Valle, J.W.; Van Cutsem, E.; Shimada, Y.; Oh, D.-Y. 2015: 134Oradiant-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (Net) of the lung or gastrointestinal (Gi) tract Annals of Oncology 26(Suppl 9): ix 40.1-ix 40
Casciano, R.; Chulikavit, M.; Perrin, A.; Liu, Z.; Wang, X.; Garrison, L.P. 2012: Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States Journal of Medical Economics 15(Suppl 1): 55-64
Neychev, V.; Steinberg, S.M.; Cottle-Delisle, C.; Merkel, R.; Nilubol, N.; Yao, J.; Meltzer, P.; Pacak, K.; Marx, S.; Kebebew, E. 2015: Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase Ii clinical trial Bmj Open 5(5): E008248
Pavel, M.E.; Hainsworth, J.D.; Baudin, E.; Peeters, M.; Hörsch, D.; Winkler, R.E.; Klimovsky, J.; Lebwohl, D.; Jehl, V.; Wolin, E.M.; Öberg, K.; Van Cutsem, E.; Yao, J.C. 2011: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Lancet 378(9808): 2005-2012
Fahey, T.J. 2012: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study Yearbook of Surgery 2012: 184-186
Apostolidis, L.; Kreutzfeldt, S.; Oles, M.; Gieldon, L.; Heining, C.; Horak, P.; Hutter, B.; Fröhlich, M.; Klink, B.; Lamping, M.; Uhrig, S.; Stenzinger, A.; Winkler, E.C.; Wiedenmann, B.; Jäger, D.; Schröck, E.; Keilholz, U.; Pavel, M.E.; Glimm, H.; Fröhling, S. 2018: Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii468